---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-002184"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-01-30T23:59:59+00:00"
generated_at: "2026-05-27T05:49:37.920506+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics reaches $2.5M SEC settlement over Dovitinib disclosure issues

## Summary
- Agreed in principle with SEC to pay $2.5M civil penalty and consent to cease-and-desist order for non-scienter securities law violations.
- Investigation concerns company's disclosures about FDA meetings for Dovitinib NDA submitted in 2021.
- Three former officers received Wells Notices; company has accrued ~$1.8M for their legal fees, with insurance coverage subject to $3.5M retention.
- Settlement is subject to final language and SEC approval; company must cooperate in any future SEC litigation.

## SEC filing metadata
- accession: 0001437749-25-002184
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-01-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925002184/0001437749-25-002184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925002184/allr20250117_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-002184
- JSON: https://secwatch.observer/filing/0001437749-25-002184.json
- Plain text: https://secwatch.observer/filing/0001437749-25-002184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.